Ergomed to present at the German Equity Forum 2017

RNS Number : 5298X

Ergomed plc

27 November 2017

 

PRESS RELEASE

Ergomed to present at the German Equity Forum 2017

London, UK - 27 November 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a specialised pharmaceutical services and drug development company, today announces its attendance at the German Equity Forum 2017 (Deutsches Eigenkapitalforum) which will be taking place at The Sheraton Frankfurt Airport Hotel & Conference Center in Frankfurt am Main, Germany, from 27 to 29 November.

Dr. Miroslav Reljanovic, Executive Vice-Chairman, will be presenting at 11:00am CET on 27 November.

ENDS

Enquiries:

Ergomed plc		Tel: [phone]
Miroslav Reljanovic (Executive Vice Chairman)
Stephen Stamp (Chief Financial Officer)
Numis Securities Limited		Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer		Tel: [phone]
Alex Price (Joint Broker)
Consilium Strategic Communications - for UK enquiries		Tel: [phone]
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Philippa Gardner	[e-mail]
MC Services - for Continental European enquiries		Tel: [phone]
Anne Hennecke

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com.

 

END

 

 

NRAUNVARBNAAUUA